KaloBios Pharmaceuticals Inc. is now free of Martin Shkreli, after the pharma 'bad boy' sold his remaining stock, and wants to get on with its work of focusing on R&D of medicines that benefit patients with rare and neglected diseases. But the firm also has some ideas it thinks could change biotech.
KaloBios Pharmaceuticals Inc. is done with Martin Shkreli. He's someone else's problem now.
Unfortunately for Mylan NV, it's currently theirs, now that Shkreli has managed to insert himself into the whole circus over the company's price increases for its emergency allergic reaction drug EpiPen (epinephrine), in which the pharma "bad boy" first called the firm "vultures," but later declared the medicine's $608 wholesale acquisition cost "quite a bargain
Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.
The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.
The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.
